Skip to main content

Table 2 Retrospective assignment of 589 patients receiving standard therapy on CALGB/Alliance trials to Beat AML genetic treatment groups

From: A precision medicine classification for treatment of acute myeloid leukemia in older patients

Assignment Performed concurrently Final assignment
Step 1 Step 2 Step 3
Initial assignment Initial assignment Reassignment
Cytogenetics VAF ≥ 0.3 VAF ≥ 0.2 Total number of patients
n (%)
Core-binding factor 74 74 (13)
NPM1m/FLT3-ITD‒ 106 1 107 (19)
KMT2A 13 13 (2)
IDH2m 56 3 59 (10)
IDH1m 33 2 35 (6)
TP53m 50 50 (9)
Complex karyotype/TP53wt 28 28 (5)
FLT3m 96 3 99 (18)
TET2m or WT1m 41 1 42 (7)
Marker-negative 66 − 10 56 (10)
Total number of assigned patients per column 115 448 10 563
  1. m, mutated; n, number; VAF, variant allele frequency; wt, wild-type